Advertisement

Amino Acids

, Volume 49, Issue 11, pp 1843–1853 | Cite as

Asymmetric dimethylarginine and symmetric dimethylarginine prospectively relates to carotid wall thickening in black men: the SABPA study

  • Catharina M. C. MelsEmail author
  • A. E. Schutte
  • H. W. Huisman
  • W. Smith
  • R. Kruger
  • J. M. van Rooyen
  • E. Schwedhelm
  • D. Atzler
  • R. H. Böger
  • N. T. Malan
  • L. Malan
Original Article

Abstract

The relationship of both asymmetric (ADMA) and symmetric (SDMA) dimethylarginine with carotid wall thickness is inconclusive especially among black populations. We aimed to compare carotid intima media thickness (cIMT) and dimethylarginine levels in 75 black and 91 white men at baseline and after a 3-year follow-up, and to investigate associations of percentage change in cIMT with percentage change in dimethylarginine levels (ADMA and SDMA). Plasma levels of ADMA and SDMA were determined with a liquid chromatography mass spectrometry method and B-mode ultrasonography was used to determine the cIMT at baseline and follow-up. In black men, mean cIMT (p = 0.79) and ADMA levels (p = 0.67) remained the same, but SDMA levels were lower (p < 0.001) when comparing baseline and follow-up. In white men, cIMT increased (p < 0.001), but both mean ADMA and SDMA levels decreased (p < 0.001) over time. In black men, percentage change in cIMT was positively associated with percentage change in ADMA (R 2 = 0.49; β = 0.46; p < 0.001) and percentage change in SDMA (R 2 = 0.46; β = 0.41; p < 0.001). These associations were absent in the white men. Despite lower mean SDMA and similar ADMA and cIMT in black men, percentage change in cIMT was independently associated with percentage change in ADMA and percentage change in SDMA. These results suggest an important role for ADMA and SDMA lowering strategies to delay carotid wall thickening, especially in black populations prone to the development of cardiovascular disease.

Keywords

Asymmetric dimethylarginine Symmetric dimethylarginine Carotid intima media thickness Carotid wall thickening Race 

Notes

Acknowledgements

The Sympathetic activity and Ambulatory Blood Pressure in Africans (SABPA) study was possible due to the voluntary participation of the teachers and the Department of Education, North West Province, South Africa. The authors thank and acknowledge the technical assistance Mrs. Tina Scholtz, Sr. Chrissie Lessing and Dr. Szabolcs Péter. Research included in the present study was partially funded by the National Research Foundation (South Africa); the Medical Research Council (South Africa); Roche Diagnostics (South Africa); the North-West University (South Africa); and the Metabolic Syndrome Institute (France).

Compliance with ethical standards

Conflict of interest

The authors have no financial or non-financial conflict of interest to declare.

Research involving human participants

The study was conducted in line with the ethical principles of the Declaration of Helsinki and was approved by the Health Research Ethics Committee of the North-West University (Potchefstroom Campus).

Informed consent

Written informed consent was obtained from all participants before commencement of the study.

Supplementary material

726_2017_2483_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 12 kb)

References

  1. Adelstein AM (1963) Some aspects of cardio-vascular mortality in South Africa. Br J Prev Soc Med 17(1):29–40PubMedPubMedCentralGoogle Scholar
  2. Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP (2015) Burden of undiagnosed hypertension in Sub-Saharan Africa. Hypertension 65(2):291–298CrossRefPubMedGoogle Scholar
  3. Atzler D, Mieth M, Maas R, Boger RH, Schwedhelm E (2011) Stable isotope dilution assay for liquid chromatography-tandem mass spectrometric determination of l-homoarginine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 879(23):2294–2298. doi: 10.1016/j.jchromb.2011.06.016 CrossRefPubMedGoogle Scholar
  4. Bahls M, Friedrich N, Atzler D, Felix SB, Nauck MA, Böger RH, Völzke H, Schwedhelm E, Dörr M (2015) l-arginine and SDMA serum concentrations are associated with subclinical atherosclerosis in the Study of Health in Pomerania (SHIP). PLoS One 10(6):e0131293CrossRefPubMedPubMedCentralGoogle Scholar
  5. Böger RH, Maas R, Schulze F, Schwedhelm E (2009) Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 60(6):481–487. doi: 10.1016/j.phrs.2009.07.001 CrossRefPubMedGoogle Scholar
  6. Buttery L, Springall D, Chester A, Evans T, Standfield E, Parums D, Yacoub M, Polak J (1996) Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 75(1):77–85PubMedGoogle Scholar
  7. Chirinos JA, David R, Bralley JA, Zea-Díaz H, Muñoz-Atahualpa E, Corrales-Medina F, Cuba-Bustinza C, Chirinos-Pacheco J, Medina-Lezama J (2008) endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease the PREVENCION study. Hypertension 52(6):1051–1059. doi: 10.1161/HYPERTENSIONAHA.108.120352 CrossRefPubMedGoogle Scholar
  8. Closs EI, Basha FZ, Habermeier A, Forstermann U (1997) Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1(1):65–73. doi: 10.1006/niox.1996.0106 CrossRefPubMedGoogle Scholar
  9. Fan NC, Tsai CM, Hsu CN, Huang LT, Tain YL (2013) N-acetylcysteine prevents hypertension via regulation of the ADMA–DDAH pathway in young spontaneously hypertensive rats. Biomed Res Int 2013:696317. doi: 10.1155/2013/696317 PubMedPubMedCentralGoogle Scholar
  10. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, Bryant TA, Chen NT, Torres-Tamayo M, Ramasamy R, Berglund L, Ginsberg HN, Homma S, Cannon PJ (2000) Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 20(9):2039–2044CrossRefPubMedGoogle Scholar
  11. Franceschelli S, Ferrone A, Pesce M, Riccioni G, Speranza L (2013) Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease. Int J Mol Sci 14(12):24412–24421. doi: 10.3390/ijms141224412 CrossRefPubMedPubMedCentralGoogle Scholar
  12. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502PubMedGoogle Scholar
  13. Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, Hirai Y, Imaizumi T (2007) Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis 191(1):206–210. doi: 10.1016/j.atherosclerosis.2006.03.022 CrossRefPubMedGoogle Scholar
  14. Goedecke JH, Utzschneider K, Faulenbach MV, Rizzo M, Berneis K, Spinas GA, Dave JA, Levitt NS, Lambert EV, Olsson T, Kahn SE (2010) Ethnic differences in serum lipoproteins and their determinants in South African women. Metab Clin Exp 59(9):1341–1350. doi: 10.1016/j.metabol.2009.12.018 CrossRefPubMedGoogle Scholar
  15. Haghikia A, Yanchev GR, Kayacelebi AA, Hanff E, Bledau N, Widera C, Sonnenschein K, Haghikia A, Weissenborn K, Bauersachs J, Bavendiek U, Tsikas D (2017) The role of l-arginine/l-homoarginine/nitric oxide pathway for aortic distensibility and intima-media thickness in stroke patients. Amino Acids 49(6):1111–1121. doi: 10.1007/s00726-017-2409-2 CrossRefPubMedGoogle Scholar
  16. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P (2001) Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci 98(7):4202–4208. doi: 10.1073/pnas.071054698 CrossRefPubMedPubMedCentralGoogle Scholar
  17. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS, Investigators C-E (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367(1):20–29. doi: 10.1056/NEJMoa1114248 CrossRefPubMedPubMedCentralGoogle Scholar
  18. Jacobi J, Maas R, Cardounel AJ, Arend M, Pope AJ, Cordasic N, Heusinger-Ribeiro J, Atzler D, Strobel J, Schwedhelm E, Boger RH, Hilgers KF (2010) Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. Am J Pathol 176(5):2559–2570. doi: 10.2353/ajpath.2010.090614 CrossRefPubMedPubMedCentralGoogle Scholar
  19. Kanazawa I, Yano S, Notsu Y, Yamaguchi T, Nabika T, Sugimoto T (2011) Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus. Clin Endocrinol 74(4):467–472. doi: 10.1111/j.1365-2265.2010.03946.x CrossRefGoogle Scholar
  20. Leone A, Moncada S, Vallance P, Calver A, Collier J (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339(8793):572–575CrossRefPubMedGoogle Scholar
  21. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM (2004) Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 94(2):157–161. doi: 10.1016/j.amjcard.2004.03.052 CrossRefPubMedGoogle Scholar
  22. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ (2011) Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 153(2):135–140. doi: 10.1016/j.ijcard.2011.06.120 CrossRefPubMedGoogle Scholar
  23. Maas R, Xanthakis V, Polak JF, Schwedhelm E, Sullivan LM, Benndorf R, Schulze F, Vasan RS, Wolf PA, Böger RH (2009) Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort. Stroke 40(8):2715–2719. doi: 10.1161/STROKEAHA.109.552539 CrossRefPubMedPubMedCentralGoogle Scholar
  24. Madaric J, Valachovicova M, Paulis L, Pribojova J, Mateova R, Sebekova K, Postulkova L, Madaricova T, Bucova M, Mistrik M, Vulev I (2017) Improvement in asymmetric dimethylarginine and oxidative stress in patients with limb salvage after autologous mononuclear stem cell application for critical limb ischemia. Stem Cell Res Ther 8(1):165. doi: 10.1186/s13287-017-0622-2 CrossRefPubMedPubMedCentralGoogle Scholar
  25. Malan L, Hamer M, Frasure-Smith N, Steyn HS, Malan NT (2015) Cohort profile: sympathetic activity and ambulatory blood pressure in Africans (SABPA) prospective cohort study. Int J Epidemiol 44(6):1814–1822. doi: 10.1093/ije/dyu199 CrossRefPubMedGoogle Scholar
  26. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 22(4):193–278CrossRefGoogle Scholar
  27. Marfell-Jones MJ, Stewart A, de Ridder J (2012) International standards for anthropometric assessment. International Society for the Advancement of Kinanthropometry, WellingtonGoogle Scholar
  28. Mels C, Schutte A, Schutte R, Huisman H, Smith W, Fourie C, Kruger R, Van Rooyen J, Malan N, Malan L (2013) The link between vascular deterioration and branched chain amino acids in a population with high glycated haemoglobin: the SABPA study. Amino Acids 45(6):1405–1413. doi: 10.1007/s00726-013-1611-0 CrossRefPubMedGoogle Scholar
  29. Mels CM, Loots I, Schwedhelm E, Atzler D, Boger RH, Schutte AE (2016) Nitric oxide synthesis capacity, ambulatory blood pressure and end organ damage in a black and white population: the SABPA study. Amino Acids 48(3):801–810. doi: 10.1007/s00726-015-2128-5 CrossRefPubMedGoogle Scholar
  30. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T (1999) Endogenous nitric oxide synthase inhibitor a novel marker of atherosclerosis. Circulation 99(9):1141–1146. doi: 10.1161/01.CIR.99.9.1141 CrossRefPubMedGoogle Scholar
  31. Morris SM Jr (1992) Regulation of enzymes of urea and arginine synthesis. Annu Rev Nutr 12(1):81–101. doi: 10.1146/annurev.nu.12.070192.000501 CrossRefPubMedGoogle Scholar
  32. Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, ter Wee PM, van Guldener C (2005) Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 68(5):2230–2236. doi: 10.1111/j.1523-1755.2005.00680.x CrossRefPubMedGoogle Scholar
  33. Peer N, Steyn K, Lombard C, Lambert EV, Vythilingum B, Levitt NS (2012) Rising diabetes prevalence among urban-dwelling black South Africans. PLoS One 7(9):e43336CrossRefPubMedPubMedCentralGoogle Scholar
  34. Perticone F, Sciacqua A, Maio R, Perticone M, Galiano Leone G, Bruni R, Di Cello S, Pascale A, Talarico G, Greco L, Andreozzi F, Sesti G (2010) Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol 142(3):236–241. doi: 10.1016/j.ijcard.2008.12.131 CrossRefPubMedGoogle Scholar
  35. Schutte AE, Schutte R, Huisman HW, Van Rooyen JM, Fourie CMT, Malan NT, Malan L, Mels CMC, Smith W, Moss SJ (2012) Are behavioural risk factors to be blamed for the conversion from optimal blood pressure to hypertensive status in black South Africans? A 5-year prospective study. Int J Epidemiol 41(4):1114–1123CrossRefPubMedGoogle Scholar
  36. Singh RB, Mengi SA, Xu YJ, Arneja AS, Dhalla NS (2002) Pathogenesis of atherosclerosis: a multifactorial process. Exp Clin Cardiol 7(1):40–53PubMedPubMedCentralGoogle Scholar
  37. Tain YL, Baylis C (2007) Determination of dimethylarginine dimethylaminohydrolase activity in the kidney. Kidney Int 72(7):886–889. doi: 10.1038/sj.ki.5002446 CrossRefPubMedPubMedCentralGoogle Scholar
  38. Tain YL, Hsu CN (2017) Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Toxins (Basel) 9(3):92. doi: 10.3390/toxins9030092 CrossRefGoogle Scholar
  39. Tain YL, Freshour G, Dikalova A, Griendling K, Baylis C (2007) Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat. Am J Physiol Renal Physiol 292(5):F1404–F1410. doi: 10.1152/ajprenal.00260.2006 CrossRefPubMedGoogle Scholar
  40. Tain YL, Huang LT, Lin IC, Lau YT, Lin CY (2010a) Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. J Pineal Res 49(4):390–398. doi: 10.1111/j.1600-079X.2010.00806.x CrossRefPubMedGoogle Scholar
  41. Tain YL, Kao YH, Hsieh CS, Chen CC, Sheen JM, Lin IC, Huang LT (2010b) Melatonin blocks oxidative stress-induced increased asymmetric dimethylarginine. Free Radic Biol Med 49(6):1088–1098. doi: 10.1016/j.freeradbiomed.2010.06.029 CrossRefPubMedGoogle Scholar
  42. Teerlink T, Luo Z, Palm F, Wilcox CS (2009) Cellular ADMA: regulation and action. Pharmacol Res 60(6):448–460. doi: 10.1016/j.phrs.2009.08.002 CrossRefPubMedPubMedCentralGoogle Scholar
  43. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS (2012) Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis 34(4):290–296. doi: 10.1159/000343145 CrossRefPubMedPubMedCentralGoogle Scholar
  44. Vallance P, Chan N (2001) Endothelial function and nitric oxide: clinical relevance. Heart 85(3):342–350CrossRefPubMedPubMedCentralGoogle Scholar
  45. van der Zwan LP, Davids M, Scheffer PG, Dekker JM, Stehouwer CD, Teerlink T (2013) l-Homoarginine and l-arginine are antagonistically related to blood pressure in an elderly population: the Hoorn study. J Hypertens 31(6):1114–1123. doi: 10.1097/HJH.0b013e32836037fb CrossRefPubMedGoogle Scholar
  46. Zsuga J, Török J, Magyar MT, Valikovics A, Gesztelyi R, Kéki S, Csiba L, Zsuga M, Bereczki D (2007) Serum asymmetric dimethylarginine negatively correlates with intima-media thickness in early-onset atherosclerosis. Cerebrovasc Dis 23(5–6):388–394. doi: 10.1159/000101461 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria 2017

Authors and Affiliations

  • Catharina M. C. Mels
    • 1
    • 2
    Email author
  • A. E. Schutte
    • 1
    • 2
  • H. W. Huisman
    • 1
    • 2
  • W. Smith
    • 1
    • 2
  • R. Kruger
    • 1
    • 2
  • J. M. van Rooyen
    • 1
    • 2
  • E. Schwedhelm
    • 3
  • D. Atzler
    • 3
    • 4
  • R. H. Böger
    • 3
  • N. T. Malan
    • 1
  • L. Malan
    • 1
  1. 1.Hypertension in Africa Research Team (HART)North-West University (Potchefstroom Campus)PotchefstroomSouth Africa
  2. 2.MRC Research Unit for Hypertension and Cardiovascular DiseaseNorth-West UniversityPotchefstroomSouth Africa
  3. 3.Department of Clinical Pharmacology and ToxicologyUniversity Medical Center Hamburg-EppendorfHamburgGermany
  4. 4.Vascular Biology, Institute for Stroke and Dementia Research, Klinikum der Universität MünchenLudwig Maximilians-University of MunichMunichGermany

Personalised recommendations